Our Blog:

30 years of cell culture excellence

Author: Biological Industries

Spotlight on iPSC production

Biological Industries sponsors RegMedNet 2-month focus on the production of iPSCs March 31, 2017 (RegMedNet.com) Induced pluripotent stem cells (iPSCs) are arguably one of the hottest topics within regenerative medicine. The first generation of iPSCs 10 years ago marked a huge milestone in the field, leading to great progress from disease modeling to development of new, personalized therapeutic approaches for numerous conditions. Key advantages include the potential low-cost manufacture of personalized medicines, omitting the need to use embryonic or fetal stem cells, efficiency of genetic manipulation compared with somatic cells and providing a source for cells that may otherwise...

Read More

Biological Industries USA Signs Agreement With Mill Creek Life Sciences To Add PLTMax Human Platelet Lysate To Its Growing Stem Cell Portfolio

PLTMax® is a superior GMP alternative to FBS supplementation for adult stem cell media Combination of PLTMax® and NutriStem® MSC Medium creates a clinically relevant culture system, offering superior growth and cellular properties for the culture of human mesenchymal stem cell (MSC) culture.   CROMWELL, Conn.–(BUSINESS WIRE)–Biological Industries USA (BI-USA), a division of Biological Industries Israel LTD, announced today a distribution agreement with Mill Creek Life Sciences LLC, a Rochester, Minnesota start-up that provides tools to support the development and application of cellular and biological therapeutics. The agreement provides for distribution of PLTMax® Human Platelet Lysate, a product derived...

Read More

cGMP: What every Life Science Researcher should know about current Good Manufacturing Practice

An interview with Ravid Grimberg, Biological Industries VP of Quality Assurance & Regulatory Affairs, Israel   Can you tell us about yourself? After finishing my bachelor’s degree in Biology and my master’s degree in Quality Assurance and Reliability from The Technion-Israel Institute of Technology, I gained experience by working in different positions in QA and RA within the pharma, cosmetic, and medical device sectors. I started working at BI because the field of cell therapy fascinates me and it gives me great fulfillment to be part of such a groundbreaking area.  Working closely together with our customers, who are often...

Read More

2016 BI-USA Year in Review

As 2016 comes to a close, we want to take this opportunity to extend our gratitude for our great new relationships. Whether you are a customer or a friend of BI and BI-USA, we appreciate the trust that you have placed in us and the opportunity to work with you throughout all of 2016. We were thrilled to announce our new US division at the end of 2015 (Biological Industries USA, Inc.). With one year under our belt, here are a few exciting highlights from our first full year: In the first quarter, BI-USA hosted several state representatives, local government,...

Read More

Biological Industries announces FDA Drug Master File Acceptance for NutriStem® hPSC XF Medium

KIBBUTZ BEIT HAEMEK, Israel and CROMWELL, CT, USA –  November 30, 2016 – Biological Industries (“BI”) announced today that the United States Food and Drug Administration (FDA) has accepted the submission for its Drug Master File (DMF) for the company’s NutriStem® hPSC XF Medium, a chemically defined, xeno-free, serum-free media, which is designed to support the growth of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). A Drug Master File (DMF) is a confidential detailed document submitted to the FDA by a manufacturer that includes the Chemistry, Manufacturing and Controls (CMC) information about their product. An...

Read More

Follow Us

Subscribe